Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

Beth Israel Lahey Health

Status and phase: Completed; Phase 2

Conditions: Prostate Cancer

Treatments: Drug: Casodex; Drug: Dexamethasone; Drug: Estramustine; Drug: Docetaxel; Drug: Zoladex; Procedure: Radical Prostatectomy

Study type: Interventional

Funder types: Other; Other U.S. Federal agency

Identifiers

NCT01250717

2001P-001577

E-99-0363-FB (Other Identifier)

Details and patient eligibility

About

The purpose of this research study is to determine if the combination of chemotherapy and hormone therapy is safe and helpful for patients who plan to have their high-risk prostate cancer surgically removed. Some physicians believe that patients with high risk cancer that is located in one area, may have an early but small spread of the cancer outside of the prostate, and perhaps even to distant organs. Therefore, better treatments for the entire body are needed to improve the ability of surgery or other local therapies to cure prostate cancer. Since chemotherapy is beginning to demonstrate increasing activity in advanced prostate cancer patients, it is possible that using chemotherapy combined with hormonal therapy earlier in the course of localized but high risk patients might improve the outcomes for these patients.

Full description

• Participants will receive treatment in the outpatient clinic, where the docetaxel chemotherapy will be placed in a bag of fluid and will be given by vein every three weeks. Participants will take Decadron (dexamethasone) by mouth 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel. They will also take estramustine and casodex by mouth at home. Zoladex (or lupron) will be given subcutaneously (under the skin) 4 times every three months. They will also be started on coumadin beginning at the time of the first docetaxel infusion and continuing until 3 weeks after the 4th cycle of chemotherapy.
• After 2 months (or cycles) of therapy, participants will be evaluated in order to assess the response and toxicity of treatment, including a review of medical history, physical examination, blood tests, including PSA. If there is no evidence of progression or excessive toxicity, treatment will continue for 2 more months in the same manner.
• At the end of 4 months of chemotherapy, participants will be reassessed by the medical oncologist and urologist regarding surgery to remove the prostate.

Enrollment: 28 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed adenocarcinoma of the prostate
• Potential candidate for radical prostatectomy
• Any of the following: a) clinical stage T3 patients, b) Serum PSA greater than or equal to 20 ng/ml, c) Gleason score 8-10, d) Clinical T2 disease and either MRI evidence of seminal vesicle involvement or Gleason 4+3 cancer with either 5 or 6 biopsies positive
• ECOG Performance Status 0-1
• WBC > 3,000 ul
• HCT > 30%
• PLT > 100,000/ul
• LFTS within normal limits

Exclusion criteria

• Prior hormones, radiation or chemotherapy for prostate cancer
• Myocardial infarction within 1 year, significant change in anginal pattern within last 6 months, current congestive heart failure (NYHA Class 2 or higher), or deep venous thrombosis within 1 year
• Evidence of active infection
• Significant peripheral neuropathy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

28 participants in 1 patient group

Docetaxel Followed by Radical Prostatectomy

Experimental group

Description:

Docetaxel,Dexamethasone,Estramustine,Zoladex,Casodex,Prostatectomy

Treatment:

Drug: Estramustine

Drug: Zoladex

Procedure: Radical Prostatectomy

Drug: Docetaxel

Drug: Dexamethasone

Drug: Casodex